MedTrace Logo

Study on TSR-042 in Advanced Clear Cell Sarcoma

NCT04274023 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-02-01

No results posted yet for this study

Summary

Phase II,single arm study designed to explore the activity of TSR-042, an immunotherapy agent, in patients with a diagnosis of advanced or metastatic clear cell sarcoma (CCS).

Conditions

  • Sarcoma, Clear Cell

Interventions

DRUG

TSR-042

TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.

Sponsors & Collaborators

Principal Investigators

  • Silvia Stacchiotti, MD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2024-01-29
Completion
2024-01-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274023 on ClinicalTrials.gov